Neurocrine Biosciences Announced Positive Results from Phase 3 CAHtalyst™ Study

Neurocrine Biosciences Announcement
Today, Neurocrine Biosciences (NBIX) announced positive top-line data from the Phase 3 CAHtalyst™ Pediatric Study evaluating the safety, efficacy and tolerability of the firm’s product crinecerfont treating children and adolescents with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
The Disease
Congenital adrenal hyperplasia refers to a group of genetic conditions that result in an enzyme deficiency that alters . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.